Two Giants Dominate IHE, Making It Riskier Than It Looks
As of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Compare ownership costs across dividend ETFs to identify which option offers the best balance of cost, yield, and risk.
22,825 articlesAs of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
A growing retirement strategy uses MLP ETFs to deliver about $34,000 a year from a $450,000 investment, while avoidin...
As investors pivot away from high-flying tech, the financial sector could offer underappreciated value. This guide ex...
Small-cap stocks are staging a comeback. This article breaks down why this small-cap outperforming still matters, how...
Chemours faces a year of nuanced cycles in pigments and fluorochemicals. This guide breaks down what to watch in chem...
March is on the horizon, and I’m paying close attention to IBM as it heads into a new earnings cycle. The century-old...
Starbucks could be on the cusp of rapid global growth, especially outside its home market. This guide explains what d...
Retirees face ongoing market swings, even when stocks look strong. Learn how to make your retirement income durable i...
The AI wave doesn’t have to ride on flashy tech stocks. This article shows how certain energy stocks can capture AI-d...
Oil markets are heating up as supply constraints tighten. Here are three solid stock ideas to consider before prices ...
AMLP delivered a record May 2026 payout and a 14% trailing return, underscoring resilient midstream cash flow. Invest...
Vanguard's VTWO and iShares' IWM both mirror the Russell 2000, but over 10 years VTWO's return outpaces IWM by roughl...